Sommario
L’iperandrogenismo e le alterazioni ormonali che sostengono i disturbi del ciclo mestruale sembrano, assieme all’obesità ed all’alterato stato insulinico, esporre le pazienti PCOS ad uno stato di ipercoagulabilità. Il rischio di tromboembolismo venoso in queste pazienti sembra coinvolgere l’emostasi secondaria, con un’incidenza che aumenta fino a 2 volte rispetto alla popolazione generale. Tuttavia, i dati epidemiologici, a disposizione, sono derivati o da coorti selezionate o da studi di registro, esponendoli a bias che non possono essere trascurati nell’interpretazione dei risultati. Infine, la letteratura disponibile ad oggi esamina l’uso di terapia estroprogestinica non includendo le formulazioni più recenti.
Abstract
Hyperandrogenism and the hormonal alterations that sustain menstrual cycle disorders appear, together with obesity and altered insulin status, to expose PCOS patients to a hypercoagulative state. This phenomenon, mainly involving secondary haemostasis, increase the risk of venous thromboembolism up to 2 times in PCOS when compared to the general population. However, the epidemiological data available are the result of studies derived from both selected cohorts or registry studies, so producing biases that cannot be overlooked in the interpretation of these results. Finally, to date, literature on the use of contraceptive pill and PCOS does not include the most recent formulations.
This is a preview of subscription content, log in via an institution to check access.
Bibliografia
Lauritsen MP, Bentzen JG, Pinborg A et al. (2014) The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone. Hum Reprod 29(4):791–801
The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2003) Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19(1):41–47
Peña AS, Witchel SF, Hoeger KM et al. (2020) Adolescent polycystic ovary syndrome according to the international evidence-based guideline. BMC Med 18:72
Moran LJ, Misso ML, Wild RA, Norman RJ (2010) Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Updat 16(4):347–363
Alvarez-Blasco F, Botella-Carretero J, San Millan J, Escobar-Morreale H (2006) Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Arch Intern Med 166:2081–2086
Chiu WL, Boyle J, Vincent A et al. (2017) Cardiometabolic risks in polycystic ovary syndrome: non-traditional risk factors and the impact of obesity. Neuroendocrinology 104(4):412–424
Heit JA (2015) Epidemiology of venous thromboembolism. Nat Rev Cardiol 12(8):464–474
Speed V, Roberts LN, Patel JP, Arya R (2018) Venous thromboembolism and women’s health. Br J Haematol 183(3):346–363
Lidegaard O, Nielsen LH, Skovlund CW, Lokkegaard E (2012) Venous thrombosis in users of non-oral hormonal contraception: follow-up study. Denmark 2001–10. BMJ 344:e2990
Targher G, Zoppini G, Bonora E, Moghetti P (2014) Hemostatic and fibrinolytic abnormalities in polycystic ovary syndrome. Semin Thromb Hemost 40(5):600–618
Scheres LJ, van Hylckama Vlieg A, Ballieux BE et al. (2019) CREW consortium. Endogenous sex hormones and risk of venous thromboembolism in young women. J Thromb Haemost 17(8):1297–1304
Arnesen CA, Veres K, Horváth-Puhó E et al. (2022) Estimated lifetime risk of venous thromboembolism in men and women in a Danish nationwide cohort: impact of competing risk of death. Eur J Epidemiol 37:195–203
Okoroh EM, Hooper WC, Atrash HK et al. (2012) Is polycystic ovary syndrome another risk factor for venous thromboembolism? United States, 2003–2008. Am J Obstet Gynecol 207(5):377.e1–377.e8
Bird ST, Hartzema AG, Brophy JM et al. (2013) Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis. Can Med Assoc J 185(2):E115–E120
Gariani K, Hugon-Rodin J, Philippe J et al. (2020) Association between polycystic ovary syndrome and venous thromboembolism: a systematic review and meta-analysis. Thromb Resc 185:102–108
Legro RS, Arslanian SA, Ehrmann DA et al. (2013) Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 98:4565–4592
Teede HJ, Misso ML, Costello MF et al. (2018) Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril 110:364–379
Oguz SH, Yildiz BO (2021) An update on contraception in polycystic ovary syndrome. Endocrinol Metab 36:296–311
LaVasseur C, Neukam S, Kartika T et al. (2022) Hormonal therapies and venous thrombosis: considerations for prevention and management. Res Pract Thromb Haemost 6:e12763
Farmer RD, Lawrenson RA, Todd JC et al. (2000) A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives. Br J Clin Pharmacol 49:580–590
de Bastos M, Stegeman BH, Rosendaal FR et al. (2014) Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev 3:CD010813
Dragoman MV, Tepper NK, Fu R et al. (2018) A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception. Int J Gynaecol Obstet 141(3):287–294
Morimont L, Haguet H, Dogné JM et al. (2021) Combined oral contraceptives and venous thromboembolism: review and perspective to mitigate the risk. Front Endocrinol (Lausanne) 12:769187
Tepper NK, Whiteman MK, Marchbanks PA et al. (2016) Progestin-only contraception and thromboembolism: a systematic review. Contraception 94(6):678–700
Rovinski D, Ramos RB, Fighera TM et al. (2018) Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: a systematic review and meta-analysis. Thromb Res 168:83–95
Seaman HE, deVries CS, Farmer RD (2003) The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study. Hum Reprod 18(3):522–526
Seaman HE, de Vries CS, Farmer RD (2004) Venous thromboembolism associated with cyproterone acetate in combination with ethinyloestradiol (Dianette): observational studies using the UK General Practice Research Database. Pharmacoepidemiol Drug Saf 13(7):427–436
Thranov SL, Lidegaard O, Nielsen LH et al. (2014) Hormonal contraception, polycystic ovary syndrome, and venous thrombosis. Eur J Contracep Repr 19(Suppl 1):S231
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflitto di interesse
Gli autori Davide Ceccato, Francesca Dassie, Pietro Maffei e Roberto Mioni dichiarano di non avere conflitti di interesse.
Consenso informato
Lo studio presentato in questo articolo non ha richiesto sperimentazione umana.
Studi sugli animali
Gli autori di questo articolo non hanno eseguito studi sugli animali.
Additional information
Proposto da A. Gambineri.
Nota della casa editrice
Springer Nature rimane neutrale in riguardo alle rivendicazioni giurisdizionali nelle mappe pubblicate e nelle affiliazioni istituzionali.
Informazioni Supplementari
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Ceccato, D., Dassie, F., Maffei, P. et al. Il rischio tromboembolico nella sindrome dell’ovaio policistico. L'Endocrinologo 25, 151–158 (2024). https://doi.org/10.1007/s40619-024-01432-9
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40619-024-01432-9